InsiderDB
Sign inStart free trial

Rep. Lisa C. McClain sold Neurocrine Biosciences (NBIX)

Rep. Lisa C. McClain (R-MI-9) · $1K–$15K · traded Jun 17, 2025

Transaction
Sold (partial)
Amount
$1K–$15K
Owner
Spouse
Traded
Jun 17, 2025
Disclosed
Aug 13, 2025
Days to disclose
57 (after the 45-day deadline)
Asset type
Stock
As filed
Neurocrine Biosciences, Inc. - Common Stock
Industry
Biotechnology · Healthcare
Official filing ↗All of McClain's tradesAll Congress trades in NBIX

Other trades in this filing

All of McClain's trades →

Recent Congress trades in NBIX

Company context for NBIX

Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.

  1. NBIXLobbying report·Lobbying disclosures

    NBIX: third_quarter 2026 lobbying report

    IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues

    Public: Oct 20, 2026, 3:14 PM EDTOriginal source ↗
  2. NBIXLobbying report·Lobbying disclosures

    NBIX: third_quarter 2026 lobbying report

    Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy

    Public: Oct 20, 2026, 2:20 PM EDTOriginal source ↗
  3. NBIXLobbying report·Lobbying disclosures

    NBIX: third_quarter 2026 lobbying report

    Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432

    Public: Oct 20, 2026, 12:10 PM EDTOriginal source ↗

From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.